LMW-PTP has been associated with the development of colorectal cancer (CRC) and with the resistance to chemotherapy in cancer cells. To clarify its role in vivo, we studied LMW-PTP expression in Pirc rats (F344/NTac-Apc When resistant cells were challenged with morin, a polyphenol inhibiting LMW-PTP, a fast and dose-related down-regulation of LMW-PTP was observed. 5-FU and morin co-treatment dramatically decreased cell viability, increased apoptosis, and significantly impaired self-renewal ability of all the cancer cell lines we have studied. Similarly, we observed that, in Pirc rats, one-week morin administration (50 mg/kg) downregulated LMW-PTP and restored the apoptotic response to 5-FU in the NM. Finally, administration of morin for a longer period led to a significant reduction in colon precancerous lesions, together with a down-regulation of LMW-PTP. Taken together, these results document the involvement of LMW-PTP in the process of CRC in vitro and in vivo. Morin treatment may be envisaged as a system to increase the sensitivity to chemotherapy and to prevent carcinogenesis.
| INTRODUCTION
Colorectal cancer, one of the main forms of cancer in Western countries, develops through sequential steps each characterized by the acquisition of genetic and epigenetic alterations leading to activation or over-expression of proteins with oncogenic activity. 1 In the past, enzymes such as protein tyrosine phosphatases were considered merely onco-suppressors, being capable to counteract the oncogenic activity of kinases. 2 In the last decades, however, a possible role as oncogenes has been proposed for some phosphatases, such as LMW-PTP, an 18 kDa protein encoded by the ACP1 gene. [3] [4] [5] Accordingly, the increased expression level of this protein has been found in colorectal cancer, as well as in other tumors. 3, 4 For colorectal cancer, it was also
shown that LMW-PTP over-expression correlates with poor prognosis. 4 In vitro, LMW-PTP has been reported to interact with various targets such as Ephrin A2 receptor (EphA2), β-catenin, and plateletderived growth factor receptors (PDGFR). [6] [7] [8] More recently, the involvement of LMW-PTP in controlling apoptosis, cell motility, and resistance to chemotherapy has been reported in colorectal cancer cells, but the role of this protein in colorectal carcinogenesis in vivo remains to be elucidated. 3 Mutations in the Adenomatous Polyposis carrying an Apc germ-line heterozygous mutation like FAP patients, spontaneously develop tumors in the colon and are thus a useful model to study carcinogenesis in the very organ in which colon cancer develops. 9, [10] [11] [12] Interestingly, the morphologically normal colon mucosa (NM) of these rats, shows resistance to apoptosis when challenged with 1,2-dimethylhydrazine (DMH), a methylating agent inducing colon cancer in rodents. 10 It is not known whether Pirc rats are resistant to other cytotoxic chemicals such as chemotherapy drugs, like 5-fluorouracil (5-FU), currently used for the treatment of CRC.
Nevertheless, these results point out that the resistance to apoptosis is not only a feature of cancerous cells but also a very early event in the process of carcinogenesis since it is already present in the Pirc NM prone to carcinogenesis.
Given the reported association between LMW-PTP and resistance to chemotherapy, together with the fact that the role of LMW-PTP in the early phases of colon carcinogenesis is not well known, we thought it of interest to study LMW-PTP expression in the normal mucosa of Pirc rats as well as in the colonic tumors, which spontaneously develop in this tumor-prone rat strain. 3, 10 Moreover, to better understand if and how LMW-PTP over-expression confers resistance to apoptosis, experiments in vitro were set up to study the expression of LMW-PTP in colon cancer cell lines differing in their resistance to chemotherapy.
These cells were also challenged with morin, a non-toxic polyphenolic compound that behaves as a non-competitive inhibitor of LMW-PTP and triggers transient degradation of LMW-PTP in cancer cells. 13 The in vitro results were then verified in vivo, using Pirc rats. Finally, since inhibition of LMW-PTP could be protective in the development of carcinogenesis, we administered morin to Pirc rats to determine whether this polyphenol could reduce colon carcinogenesis. To study resistance to apoptosis in Pirc and wt rats, we used 8-week-old Pirc and age-matched wt rats that were treated with 70 mg/kg (s.c.) of 5-Fluorouracyl (5-FU) and euthanized 24 h later as described below. The effect of morin (Sigma-Aldrich) treatment on the apoptotic response to 5-FU was studied in eight Pirc rats (aged 9 months) who were randomly allocated to: Controls (four rats), fed the standard AIN-76 diet or morin-treated (four rats), fed for 1 week the same AIN-76 diet supplemented with morin to provide a dose of 50 mg/kg (body weight). The last day of the treatment week, rats (both Controls and morin-treated) were treated (s.c.) with 5-FU (50 mg/kg) and euthanized 24 h later to measure apoptosis and LMW-PTP expression as described below.
| MATERIALS AND METHODS

| Animals and treatments
The chemopreventive activity of morin was tested in 18 male Pirc rats that were randomly allocated at 1 month of age to the standard AIN-76 diet (Controls, n = 9), or to the same diet supplemented with morin (n = 9) to provide 50 mg/kg (body weight). This dose of morin was chosen based on previous carcinogenesis experiments with morin or with polyphenolic extracts from various sources. 14, 15 Similarly, the choice to administer morin mixed in the diet was based on previous experiments using this protocol to test potential chemopreventive agents. 16, 17 The diet containing morin was prepared weekly adjusting the quantity of morin to be added on the basis of the amount of diet eaten daily by rats and on their body weight determined each week.
Animals were euthanized at 10 weeks of age, and the chemopreventive activity of morin determined comparing the number of preneoplastic lesions mucin depleted foci (MDF) in Controls and morintreated animals. 10, 18, 19 The number of animals/group depends on the size of the expected effects in each specific experiment. Regarding the experiment on the apoptotic response to 5-FU, the low number of animals is based on the expected large difference between wt rats and Pirc rats (as previously observed in Pirc rats and wt rats treated with DMH). 10 Therefore, we considered that four rats would be sufficient to observe a significant difference, this also in light of a reduction in the number of animals to be used (3R principle). Regarding the chemoprevention experiment with morin, we were unaware of the size of this effect and so we had to rely on a larger number of animals to obtain a statistically significant effect, and to avoid the risk to nullify the experiment and to waste animals. All the animals used in the study were male.
| Determination of MDF
The entire colon was dissected, flushed with cold saline, longitudinally opened and fixed flat in formalin for at least 18 h. The colon was then stained with High-Iron Diamine Alcian blue (HID-AB) technique to determine MDF at the microscope. 10 As previously documented, staining the whole unsectioned colon with HID-AB, it allows to highlight mucin production at the opening of normal crypts; MDF which shows a defective mucous production, can be easily visualized as foci of crypts lacking HID-AB staining. 
| Polyclonal LMW-PTPs antibodies production
Antisera were obtained by immunizing rabbits with the synthetic
peptides [T S G Y E I G N P P D Y R G Q] and [V S D W N V G R S P D P R
A V], respectively designed from the isoform-specific domain of IF1/ LMW-PTP and IF2/ LMW-PTP (SIGMA-GENOSYS, Custom Peptide Antisera Services).
Isoform specific antibodies were purified from the immunoglobulin fraction by affinity chromatography using Sepharose 4B coupled with the pure IF1/LMW-PTP protein or IF2/LMW-PTP protein as immunoadsorbent. The purified antibodies were characterized with respect to their specificity and sensitivity by immunoblotting.
| Determination of LMW-PTP expression in the colon mucosa and tumors
Morphologically normal mucosa from Pirc rats and age-matched wt rats (8 weeks of age) was stored in RNA-later™ (Qiagen) at −80°C until analysis (n = 7 and 9 for wt and Pirc rats, respectively).
The expression of LMW-PTP in colon tumors was evaluated in archival samples stored in RNA-later™ (Qiagen) at −80°C from Pirc rats aged 9 months (n = 7).
All samples were sonicated on ice in 300 μL of RIPA buffer (50 mM TrisHCl pH 7,5, 150 mM NaCl, 100 mM NaF, 2 mM EGTA, 1% Triton X-100, 10 μL/mL Protease and Phosphatase inhibitor, Sigma). Lysates were centrifuged at 4°C, 14 000 rpm for 15 min: 
| Determination of cell viability
MTT assay (Sigma-Aldrich) was used to measure cell viability. Cells were incubated with 0.5 mg/mL MTT solution for 1 h at 37°C. After removing cell culture medium, DMSO was added to dissolve the insoluble MTT-formazane salt. Results were detected at 595 nm on a microplate reader (BioRad). 
| Annexin V and propidium iodid assay
| Colony formation assay
After 24 h treatment, 1000 cells were seeded into a six-well plates and cultured for 9-11 days. Subsequently, cells were fixed and stained with a solution containing 1% crystal violet (Sigma-Aldrich) and 10% methanol. Colonies were photographed and counted using ImageJ imaging system.
| Statistical analysis
Data are presented as means ± SE. The data of the in vitro experiments are from at least three independent experiments; the number of animals for each in vivo experiment is specified in the legends to the figures. Statistical analysis of the data was performed by Student's t test or 2-way ANOVA (Bonferroni corrected). P values of ≤0.05 were considered statistically significant.
| RESULTS
| Expression of LMW-PTP in the apparently normal mucosa of Pirc rats and in colon tumors
Pirc rats bearing Apc mutation spontaneously develop several colon tumors in their life. [9] [10] [11] [12] 22 To confirm the involvement of LMW-PTP in colon carcinogenesis and to study its expression in the early phases of this process, we evaluated expression levels of this enzyme both in the morphologically NM and in spontaneously developed colon tumors in Pirc rats. Surprisingly, we find that expression levels of LMW-PTP in the NM of Pirc rats are dramatically higher when compared with those detected in the NM of wt rats. Moreover, considering Pirc rats, we observe that colon tumors express higher LMW-PTP levels with respect to their corresponding normal mucosa ( Figures 1A and 1B) .
These results indicate that Apc mutated cells express high LMW-PTP levels, regardless they are in the apparently normal mucosa or in tumors.
To gain more insight into the role of LMW-PTP, we also evaluated the sensitivity of Pirc rats to apoptosis induced by 5-FU, a pyrimidine analog, commonly used in the treatment of colon cancer. 23 To this aim, 
| In vivo pre-treatment with morin enhances apoptotic response in Pirc normal mucosa
To evaluate the effectiveness of morin in enhancing apoptotic response also in vivo, we studied its effects in Pirc rats. Morin (50 mg/kg) was administrated to rats mixed in the diet for 1 week before treatment with a single dose of 5-FU (50 mg/kg). 24 h after 5-FU treatment, the animals were euthanized to evaluate the number of apoptotic cells in the colon ( Figure 7A ). We observe that the number of apoptotic cells is higher in the rats pre-treated with morin compared with control rats not treated with morin ( Figure 7B and Supplementary Figure S1 ). At the same time, testing LMW-PTP expression in the NM of Pirc rats pre-treated with morin, we find a statistically significant lower expression of LMW-PTP compared with Pirc rats not treated with morin ( Figures 7C and 7D) , confirming that morin down-regulates 
| Morin treatment reduces colon precancerous lesions in Pirc rats
Finally, we evaluated whether morin is able to inhibit colon 
| DISCUSSION
The ability to resist to death stimuli, a hallmark of the cancerous cell, may cause resistance to chemotherapy agents in CRC, leading to a consequent failure of cancer therapy. 24, 25 Resistance to apoptotic stimuli is also important in the early phases of cancer development since it may allow the growth of defective cells that would be otherwise eliminated by apoptosis. 20, 26, 27 We have previously documented that the morphologically normal colon mucosa of Pirc rats, (rats that are prone to carcinogenesis via a heterozygous mutation in Apc gene) is resistant to apoptosis. In fact, Pirc NM, when challenged with a toxic dose of DMH, shows low levels of apoptosis and fails to stop proliferation. 10 In the present paper, we show that the NM of Pirc rats overexpresses LMW-PTP when compared to the NM of wt rats.
LMW-PTP over-expression has been reported so far in several types of cancer, including CRC, as we showed in clinical colon cancer samples and in rodent DMH-induced colon cancers. involving an increase of apoptosis. [34] [35] [36] [37] [38] Based on these strong effects of morin in CRC cells in vitro, we then tested whether morin could restore the apoptotic response in Pirc 
with t-test
We also show that morin, administered for 6 weeks to Pirc rats, decreases the number of preneoplastic MDF in the colon. This result is in agreement with reports showing that morin, (administered at the same dosage of the present study) may decrease colon carcinogenesis when given chronically (up to 30 weeks of treatment) to carcinogen-initiated rats. 15, 39 Since morin is present in some fruits, 40, 41 one could wonder how our study relates to a modulation of cancer risk just with the diet. Dietary consumption of vegetable and fruits (both rich in polyphenolic compounds) has been associated with a lower risk of CRC, but it is thought that this beneficial effect is due to the presence in these foods of several compounds (eg, fibers, for one thing) and certainly not just to a single polyphenol like morin, which is present in small quantity in foods. 42, 43 In the present study morin was used since it is a potent inhibitor of LMW-PTP in vitro, and, as we show, it also acts in vivo to lower LMW-PTP and to decrease carcinogenesis. Although the dose we used is higher than the presumed dietary intake of morin in humans, since morin is not toxic, these studies suggest that morin treatment (as supplement) could be envisaged as a strategy to prevent CRC in subjects at high risk such as those operated for CRC or FAP patients. Furthermore, the results of the experiments with 5-FU and morin co-treatment suggest the possibility of a therapeutic use of morin as a sensitizing agent to potentiate anticancer drug effectiveness in humans.
Various mechanisms have been implicated in this protective effect of morin (ie, variation in fecal and mucosal enzymes, in tissue and serum lipids, or in Myc expression), but none of these studies investigated the expression of LMW-PTP and apoptosis. 15, 42, 43 Here we show that morin is able to lower LMW-PTP expression in the colon mucosa in agreement with our in vitro findings. In addition, we find that in the tumors from animals treated with morin, apoptosis is higher than in those from control animals, suggesting that this phenomenon might selectively favor the elimination of defective cells during carcinogene-
sis. An increase in apoptosis in tumors, has been described as a mechanism through which chemopreventive agents act in the colon. 30, 44, 45 Interestingly, basal levels of apoptosis in the normal mucosa are not affected by morin.
In conclusion, we show for the first time that the preneoplastic mucosa of Pirc rats, prone to carcinogenesis and resistant to apoptosis, over-expresses LMW-PTP, a protein with oncogenic potential. We also show that morin is an inhibitor of LMW-PTP in colon cancer cells and that this inhibitor restores the sensitivity to apoptosis and it decreases other characteristics of malignancy in these cells.
Importantly, we document that the same effects observed in vitro can be reproduced in vivo in Pirc rats where morin restores the sensitivity to apoptosis and lowers LMW-PTP.
Finally, we show that morin decreases the spontaneous formation of colonic preneoplastic lesions when given chronically to Pirc rats; the mechanism involves a selective increase in apoptosis in tumor cells and a down-regulation of LMW-PTP.
| CONCLUSION
Taken together these results document the involvement of LMW-PTP in the process of colon carcinogenesis both in the early and in the late phases of this process. Morin treatment may be envisaged as a system to increase the sensitivity to chemotherapy and to prevent carcinogenesis in patients at risk to develop CRC.
FIGURE 9
Morin increases apoptosis in colon tumors. Apoptosis in the tumors of Pirc rats treated for 6 weeks with morin or with a standard rodent diet. Bars are mean values ± SE. (Control group, n = 6; morin group n = 5). * P < 0.05
